Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial

Demetri, G.D.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Joensuu, H.; Maki, R.G.; ... ; GRID Invest (2012)

Article / Letter to editor

• All authors: Demetri, G.D.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Joensuu, H.; Maki, R.G.; Rutkowski, P.; Hohenberger, P.; Gelderblom, H.; Leahy, M.G.; Mehren, M. von; Schoffski, P.; Blackstein, M.E.; Cesne, A. le; Badalamenti, G.; Xu, J.M.; Nishida, T.; Laurent, D.; Kuss, I.; Casali, P.G.; GRID Invest
• Date: 2012-05-20
• Journal: Journal of Clinical Oncology
• Volume: 30
• Issue: 15